TEM - Tempus AI Inc
Executive Summary
Tempus AI Inc (TEM) is a US-based technology company that applies artificial intelligence to precision medicine, with its principal operations spanning AI-enabled laboratory diagnostics, genomic sequencing services and the monetisation of de-identified clinical and molecular data through licensing arrangements to pharmaceutical and biotechnology customers. The group sits within the software-application segment of the broader technology sector and has positioned itself as a meaningful participant at the intersection of clinical genomics, AI infrastructure and real-world evidence, though specific market-share rankings have not been independently verified in the data reviewed.
The investment case rests on a cluster of identifiable hard catalysts that have already begun to print: multi-hundred-million-dollar data-licensing wins, the integration of the Personalis acquisition, and a string of FDA clearances that together underpinned raised full-year 2026 guidance and a first reported Adjusted EBITDA-positive Q2 2026 print. The key near-term swing factor is execution against that raised revenue and Adjusted EBITDA guidance for 2026, with the next quarterly update (the Q3 2026 results) acting as the principal scheduled catalyst. The primary risk is that GAAP profitability remains elusive, with issuer filings continuing to disclose material stock-based compensation expense and net losses that could re-rate the equity sharply lower if the adjusted-profitability narrative breaks.
BUY. Conviction Score: 66/100. The view would be downgraded if a quarterly print were to miss the raised 2026 revenue or Adjusted EBITDA guidance, or if a material data-licensing customer were to walk away from an existing arrangement.
Thesis break: The thesis would be invalidated by a quarterly miss against the raised full-year 2026 revenue guide of $1.59 - 1.60 billion or the ~$65 million full-year 2026 Adjusted EBITDA guide, the loss or non-renewal of a named multi-hundred-million-dollar data-licensing customer, or a material deterioration in GAAP results driven by stock-based compensation that breaks the adjusted-profitability inflection narrative.
Business Model
Tempus AI generates revenue primarily through two interrelated streams: a Genomics segment, which provides AI-enabled diagnostic testing (notably its xT, xR and related oncology panels) to oncologists, hospitals and other clinicians, and a Data and Services segment, which monetises the company's library of de-identified clinical, imaging and molecular data through licensing and partnership agreements with pharmaceutical, biotechnology and selected diagnostic customers. Customers therefore fall into two distinct groups: clinical end-users (hospitals, oncology practices and individual clinicians ordering tests) on the genomics side, and life-sciences counterparties (drug developers and research institutions) on the data side. The data and services book tends to carry materially higher gross margins than the laboratory-testing book, which is why segment mix is one of the more important levers in the model.
In the most recently reported quarter prior to today, Q1 2026, group revenue increased 75.4% year-on-year to $255.7 million, with gross profit up 99.8% year-on-year to $155.2 million and continued gross-margin expansion across both the Genomics and Data and Services segments. Management subsequently raised full-year 2026 revenue guidance to $1.59 - 1.60 billion and indicated full-year 2026 Adjusted EBITDA of approximately $65 million, a level that would represent a meaningful profitability inflection versus prior periods in which GAAP results were dominated by stock-based compensation. The competitive moat, where one exists, sits in the combination of accumulated clinical data assets, regulatory clearances and integrated AI workflows rather than in any single piece of intellectual property, which means the durability of the franchise depends on continued reinvestment and on maintaining the trust of both clinical and pharmaceutical counterparties.
Financial Snapshot
Recent Catalysts
[2026-07-30] - Tempus AI filed a Form 8-K with the SEC disclosing its second-quarter 2026 financial results, with the accompanying exhibit titled "Tempus Reports Second Quarter 2026 Results" indicating a quarterly print that included an Adjusted EBITDA profitability inflection referenced in management's commentary. Source: SEC Form 8-K filing (tem-20260730.htm) and Exhibit 99.1.
[Q1 2026 reporting period, 2026-05-05] - Tempus reported first-quarter 2026 results, with revenue of $255.7 million (up 75.4% year-on-year), gross profit of $155.2 million (up 99.8% year-on-year) and management simultaneously raising full-year 2026 revenue guidance to $1.59 - 1.60 billion with full-year 2026 Adjusted EBITDA guided to roughly $65 million. Source: BusinessWire press release dated 5 May 2026, "Tempus Reports First Quarter 2026 Results".
[2026-06-03] - Tempus issued a corporate press release dated 3 June 2026, dated out of Chicago, referencing clinical availability and product developments consistent with the company's ongoing diagnostics and data platform expansion. Source: Tempus corporate news release dated 3 June 2026 (tempus.com news page).
[2026-06-04] - TEM shares moved sharply higher during the 4 June 2026 trading session following an FDA-related announcement, with press coverage indicating the move was tied to a regulatory clearance supporting the company's growth narrative. Source: StocksToTrade news article dated 4 June 2026.
[2026-06-01] - Wolfe Research, via TipRanks, assumed coverage of Tempus AI with a Peer Perform rating, marking a notable sell-side initiation event for the stock during the period. Source: TipRanks summary dated 1 June 2026.
[2026-08-06] - Tempus AI's next earnings announcement was scheduled for 6 August 2026, after the close, per TipRanks' earnings calendar; this date is a confirmed past date relative to today's date of 4 October 2026 and the corresponding print has already occurred as the 30 July 2026 8-K referenced above. Source: TipRanks earnings calendar entry for TEM.
Thesis Evaluation
Bull Case (33% weight)
Data-licensing contracts continue to ramp beyond the $200 million-plus already disclosed, the Personalis integration delivers cross-sell into Tempus's existing genomics customer base, and the FDA clearances secured in 2026 catalyse incremental assay adoption in oncology. Under these conditions revenue compounds toward and through the upper end of the raised 2026 guidance range and adjusted profitability scales further, supporting a price target of $112 over a 12-month horizon.
Base Case (51% weight)
The most likely outcome is that Tempus delivers the raised full-year 2026 revenue guidance of $1.59 - 1.60 billion, lands roughly at the guided ~$65 million of full-year 2026 Adjusted EBITDA, and reports continued GAAP losses driven by stock-based compensation while data-licensing momentum normalises into 2027. On that path the share price is likely to re-rate modestly higher as the profitability-inflection narrative is confirmed, with a price target of $88 over a 12-month horizon.
Bear Case (16% weight)
Execution disappoints, a material data-licensing customer reduces or terminates an existing arrangement, or stock-based compensation remains elevated enough to keep GAAP losses substantial, which would unwind the adjusted-EBITDA narrative and force a sharp de-rating. In that scenario the share price retraces toward $48 over a 12-month horizon.
Key Risks
- Persistent GAAP losses driven by stock-based compensation: Issuer filings disclose ongoing net losses including material stock-based compensation and related employer payroll taxes, which keep GAAP profitability elusive even as Adjusted EBITDA turns positive. Estimated probability: 60%. Impact: moderate.
- Customer concentration and data-licensing renewal risk: A meaningful share of growth is tied to a relatively small number of multi-hundred-million-dollar data-licensing arrangements, creating concentration risk if a key counterparty reduces, terminates or fails to renew. Estimated probability: 30%. Impact: severe.
- Valuation stretched relative to consensus and current trading: The share price sits above the $70.06 consensus target referenced in the analyst reasoning and is well off the 52-week low of $40.77, leaving limited margin of safety if sentiment turns. Estimated probability: 45%. Impact: moderate.
- M&A integration risk from the Personalis transaction: The Personalis acquisition expands the diagnostic footprint but introduces integration, retention and synergy-realisation risk that could weigh on margins if execution falters. Estimated probability: 35%. Impact: moderate.
- Regulatory and reimbursement uncertainty: Future FDA decisions, CMS reimbursement coverage determinations and payor policy changes can materially alter the unit economics of AI-enabled diagnostic assays. Estimated probability: 40%. Impact: moderate.
- Volatility and historical-price-range risk: The stock has traded within a wide 52-week range of $40.77 to $104.32, implying material drawdown risk during broad technology-sector or growth-equity sell-offs. Estimated probability: 50%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: long-biased growth investors with a minimum 12-month holding horizon, a high tolerance for GAAP losses and continued stock-based compensation dilution, and a willingness to underwrite ongoing execution against raised 2026 revenue and Adjusted EBITDA guidance. The position is best suited to investors who already accept that the bull case depends on data-licensing momentum, FDA-driven assay adoption and the successful integration of the Personalis acquisition, and who can tolerate the wide $40.77 - $104.32 trading range without being forced sellers on drawdowns.
Avoid if: you require near-term GAAP profitability, a clean balance sheet without reliance on continued capital-markets access, or low-volatility exposure within the technology sleeve. Investors with strict drawdown limits, those restricted from holding unprofitable or recently IPO'd equities, or anyone who would be forced to liquidate on a re-test of the 52-week low should not hold this name.
Recommendation
BUY - 66/100. The recommendation reflects a balance between identifiable and largely already-printed hard catalysts (multi-hundred-million-dollar licensing wins, Personalis M&A, multiple FDA clearances, raised 2026 guidance and a Q2 2026 Adjusted EBITDA inflection) on one side, and on the other side the documented risks of persistent GAAP losses, elevated stock-based compensation and a share price that already sits above the $70.06 consensus target. The call would be upgraded if Tempus delivers a clean beat-and-raise quarter that pushes 2026 Adjusted EBITDA materially above the ~$65 million guide while data-licensing momentum accelerates, or downgraded if a quarterly result misses the raised revenue or Adjusted EBITDA guidance, a material licensing customer reduces exposure, or integration of Personalis weighs visibly on margins. At the current price of $75.89 the shares trade above our buy ceiling of $61.33: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is $89.52, 18% above the current price of $75.89 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $61.33 - below this level the upside to the base-case target ($88.00) is at least 2x the downside to the bear case ($48.00), the minimum risk/reward we require before committing new capital.
between $61.33 and $88.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $88.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 33%.
if the thesis would be invalidated by a quarterly miss against the raised full-year 2026 revenue guide of $1.59 - 1.60 billion or the ~$65 million full-year 2026 Adjusted EBITDA guide, the loss or non-renewal of a named multi-hundred-million-dollar data-licensing customer, or a material deterioration in GAAP results driven by stock-based compensation that breaks the adjusted-profitability inflection narrative, regardless of price - the bear target of $48.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 66/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-10-04 | 66 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow, company earnings press releases, regulatory filings, investor day and corporate communications materials, web research coverage and aggregated sell-side analyst commentary drawn from publicly available channels.
Primary source types: SEC filings (Form 8-K and exhibits filed via EDGAR), earnings call press releases distributed via BusinessWire and the Tempus corporate newsroom, company investor relations materials and corporate press releases, regulatory clearances disclosed through company channels, and third-party financial news and earnings-calendar coverage.
Key sources
- Tempus AI (TEM) Earnings Date and Reports 2026 $TEM
- Tempus AI, Inc. (TEM) Stock Price, News, Quote & History - Yahoo Finance
- News Releases | Tempus AI
- Tempus AI (TEM) Stock Price & Overview
- Tempus Reports Second Quarter 2026 Results
- Tempus Reports Second Quarter 2026 Results
- Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model | Tempus AI
- Stock is the default in Tempus AI (TEM)'s proposed Personalis merger, but cash is an option.
- TEM Surges Into $1.5B MRD Deal As Stock Pulls Back - StocksToTrade
- Tempus Reports First Quarter 2026 Results | Tempus AI
Analysis generated 2026-10-04. Market data as of 2026-11-12.